Katherine W Reeves1, Michael Pennell2, Randi E Foraker3, Carolyn J Crandall4, Marcia Stefanick5, Electra D Paskett6,7. 1. Department of Biostatistics and Epidemiology, University of Massachusetts, 411 Arnold House, 715 North Pleasant Street, Amherst, MA, 01003, USA. kwreeves@schoolph.umass.edu. 2. Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH, USA. 3. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA. 4. Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA. 5. Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA, USA. 6. The Division of Cancer Prevention and Control, Ohio State University, Columbus, OH, USA. 7. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Abstract
PURPOSE: Vasomotor symptoms (VMS) are a common side effect of breast cancer treatment, yet modifiable factors that may predict VMS among breast cancer survivors are unknown. METHODS: We estimated multivariable-adjusted odds ratios and 95% confidence intervals (aOR, 95% CI) for predictors of VMS among 3595 breast cancer survivors enrolled in the Life and Longevity after Cancer (LILAC) study, an ancillary study of the Women's Health Initiative (WHI). RESULTS: VMS post-diagnosis were reported by 790 (22.0%) participants. Risk of VMS after diagnosis was positively associated with prior chemotherapy (aOR 1.80, 95% CI 1.21-2.68) and adjuvant hormone therapy (aOR 2.73, 95% CI 2.08-3.58), postmenopausal hormone therapy use (aOR 1.67, 95% CI 1.30-2.13), prior VMS (aOR 2.20, 95% CI 1.73-2.80), bilateral oophorectomy (aOR 1.77, 95% CI 1.37-2.27), and baseline antidepressant use (aOR 1.49, 1.06-2.09). VMS post-diagnosis were less likely among younger women (aOR 0.94, 95% CI 0.93-0.96), women younger at menopause (aOR 0.98, 95% CI 0.97-1.00), women with more time since diagnosis (aOR 0.92, 95% CI 0.90-0.94), and diabetics (aOR 0.45, 95% CI 0.21-0.95). Metabolic syndrome was not associated with post-diagnosis VMS (aOR 0.76, 95% CI 0.45-1.28). CONCLUSIONS: VMS following breast cancer diagnosis was related to a number of modifiable factors, but was unrelated to metabolic syndrome. IMPLICATIONS FOR CANCER SURVIVORS: Identification of factors that predispose women to VMS following a breast cancer diagnosis may allow clinicians to recognize and address VMS in the subset of women who are most likely to experience such symptoms.
PURPOSE: Vasomotor symptoms (VMS) are a common side effect of breast cancer treatment, yet modifiable factors that may predict VMS among breast cancer survivors are unknown. METHODS: We estimated multivariable-adjusted odds ratios and 95% confidence intervals (aOR, 95% CI) for predictors of VMS among 3595 breast cancer survivors enrolled in the Life and Longevity after Cancer (LILAC) study, an ancillary study of the Women's Health Initiative (WHI). RESULTS: VMS post-diagnosis were reported by 790 (22.0%) participants. Risk of VMS after diagnosis was positively associated with prior chemotherapy (aOR 1.80, 95% CI 1.21-2.68) and adjuvant hormone therapy (aOR 2.73, 95% CI 2.08-3.58), postmenopausal hormone therapy use (aOR 1.67, 95% CI 1.30-2.13), prior VMS (aOR 2.20, 95% CI 1.73-2.80), bilateral oophorectomy (aOR 1.77, 95% CI 1.37-2.27), and baseline antidepressant use (aOR 1.49, 1.06-2.09). VMS post-diagnosis were less likely among younger women (aOR 0.94, 95% CI 0.93-0.96), women younger at menopause (aOR 0.98, 95% CI 0.97-1.00), women with more time since diagnosis (aOR 0.92, 95% CI 0.90-0.94), and diabetics (aOR 0.45, 95% CI 0.21-0.95). Metabolic syndrome was not associated with post-diagnosis VMS (aOR 0.76, 95% CI 0.45-1.28). CONCLUSIONS: VMS following breast cancer diagnosis was related to a number of modifiable factors, but was unrelated to metabolic syndrome. IMPLICATIONS FOR CANCER SURVIVORS: Identification of factors that predispose women to VMS following a breast cancer diagnosis may allow clinicians to recognize and address VMS in the subset of women who are most likely to experience such symptoms.
Entities:
Keywords:
Breast cancer; Metabolic syndrome; Treatment; Vasomotor symptoms
Authors: Ellen B Gold; Alicia Colvin; Nancy Avis; Joyce Bromberger; Gail A Greendale; Lynda Powell; Barbara Sternfeld; Karen Matthews Journal: Am J Public Health Date: 2006-05-30 Impact factor: 9.308
Authors: Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen B Gold; Barbara Sternfeld; Hadine Joffe; Faith Selzer; Karen A Matthews Journal: Obstet Gynecol Date: 2012-04 Impact factor: 7.661
Authors: Emily D Szmuilowicz; JoAnn E Manson; Jacques E Rossouw; Barbara V Howard; Karen L Margolis; Nancy C Greep; Robert G Brzyski; Marcia L Stefanick; Mary Jo O'Sullivan; Chunyuan Wu; Matthew Allison; Diederick E Grobbee; Karen C Johnson; Judith K Ockene; Beatriz L Rodriguez; Gloria E Sarto; Mara Z Vitolins; Ellen W Seely Journal: Menopause Date: 2011-06 Impact factor: 2.953
Authors: Anna Kemp; David B Preen; Christobel Saunders; Frances Boyle; Max Bulsara; Eva Malacova; Elizabeth E Roughead Journal: Springerplus Date: 2014-06-04
Authors: Ellen B Gold; Sybil L Crawford; Katherine Leung; Gail Greendale; Katherine W Reeves; Hadine Joffe; Nancy E Avis Journal: Breast Cancer Res Treat Date: 2021-10-25 Impact factor: 4.624